ClinConnect ClinConnect Logo
Search / Trial NCT06794996

Phase 2b Open-label Study of Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease

Launched by VERTEX PHARMACEUTICALS INCORPORATED · Jan 23, 2025

Trial Information

Current as of October 03, 2025

Recruiting

Keywords

Apol1 Mediated Kidney Disease (Amkd)

ClinConnect Summary

This clinical trial is studying a medication called Inaxaplin (IXP) to see how well it works and how safe it is for people with a specific type of kidney disease known as proteinuric APOL1-mediated kidney disease. This condition can lead to kidney damage, and the researchers want to find out if Inaxaplin can help improve kidney function in affected individuals.

To participate, you need to be between the ages of 65 and 74 and have a specific genetic makeup (APOL1 genotype) that makes you more susceptible to this kidney disease. Additionally, your kidney function, measured by something called the estimated glomerular filtration rate (eGFR), should be at least 25 mL/min. If you join the trial, you can expect to undergo regular check-ups to monitor your health and kidney function while taking the medication. The trial is currently recruiting participants, and if you have any questions or think you might be eligible, it's a good idea to discuss it with your healthcare provider.

Gender

ALL

Eligibility criteria

  • Key Inclusion Criteria:
  • Participant has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex designated investigational clinical study assay
  • Estimated Glomerular Filtration Rate (eGFR) of greater than or equal to (≥) 25 milliliter per minute (mL/min)/1.73m\^2 at screening
  • Key Exclusion Criteria:
  • Evidence of Focal Segmental Glomerulosclerosis (FSGS) with a known cause other than due to APOL1 risk variants
  • Uncontrolled hypertension
  • Other protocol defined Inclusion/Exclusion criteria may apply.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is a global biotechnology company dedicated to the innovation and development of transformative therapies for serious diseases, particularly those with significant unmet medical needs. Founded in 1989 and headquartered in Boston, Massachusetts, Vertex specializes in the research and commercialization of treatments for cystic fibrosis and other genetic disorders. Leveraging cutting-edge science and a commitment to patient-centric solutions, Vertex collaborates with healthcare professionals and researchers to advance clinical trials and bring groundbreaking therapies to market, aiming to improve the lives of patients worldwide.

Locations

Columbus, Mississippi, United States

Tupelo, Mississippi, United States

Columbia, South Carolina, United States

Baton Rouge, Louisiana, United States

Lauderdale Lakes, Florida, United States

Laurelton, New York, United States

Huntsville, Alabama, United States

Lawrenceville, Georgia, United States

Columbus, Georgia, United States

Houston, Texas, United States

Metairie, Louisiana, United States

New Bern, North Carolina, United States

Shreveport, Louisiana, United States

Chapel Hill, North Carolina, United States

Spartanburg, South Carolina, United States

Cary, North Carolina, United States

New York, New York, United States

Silver Spring, Maryland, United States

Dallas, Texas, United States

Dallas, Texas, United States

Dallas, Texas, United States

Las Vegas, Nevada, United States

Norfolk, Virginia, United States

Fayetteville, Georgia, United States

Savannah, Georgia, United States

Newark, New Jersey, United States

Orlando, Florida, United States

Hollywood, Florida, United States

Dallas, Texas, United States

New Orleans, Louisiana, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported